

Lincolnshire Prescribing and Clinical Effectiveness Bulletin – Vol 13 No 12

November 2019

Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

<u>Table of Contents</u>	
DRUG ASSESSMENT SUMMARY	
Toujeo DoubleStar® pen approved for inclusion on the formulary as AMBER 2; prescribe by brand name only to avoid confusion.	Page 2
Sorprobec® inhaler approved for inclusion on the formulary as first line for “beclomethasone only” MDI, with a GREEN status.	Page 2
Kelhale® inhaler approved for inclusion on the formulary as first line for beclomethasone dipropionate (extrafine aerosol) MDI, for adults only (individuals 18 years and over), with a GREEN status.	Page 3
UPDATES	
Antimicrobial guidelines	Page 3
Pain Management Guidance & Quick Reference Guide	Page 3

DRUG ASSESSMENT SUMMARY

Product	Summary	Decision
Toujeo DoubleStar® pen	<p>Introduction: Toujeo SoloStar is on the formulary listed as AMBER 2. Toujeo SoloStar contains 300units/ml of insulin glargine in a pre-filled pen containing 1.5ml solution for injection. Toujeo DoubleStar is a high volume formulation, containing the same strength of insulin glargine (300units/ml) but double the volume (3ml). There is a difference in terms of how the dose is delivered. The SoloStar device can deliver any dose up to 80 units, in increments of one unit. The DoubleStar device can deliver doses from 2–160 units in increments of 2 units. The Solostar can deliver any dose up to 80 units while the DoubleStar device can only deliver even numbered doses up to a maximum of 160 units. When changing from Toujeo SoloStar to ToujeoDouble Star, if the patients dose was an odd number e.g. 23 units then the dose must either be decreased or increased by 1 e.g. 22 units or 24 units.</p> <p>Further relevant information: There is a risk involved due to the differences in doses which can be administered. Each dose step on each device is identified by one click. If patients rely on series of clicks to identify doses there could be potential for incorrect dose being delivered if wrong device supplied. The company have recognised this and produced educational materials aimed at health care professionals and separate information aimed at patients and carers.</p>	<p>Approved for inclusion on the formulary as AMBER 2; prescribe by brand name only to avoid confusion.</p>
Soprobec® inhaler	<p>Introduction: Soprobec® is a new brand of beclomethasone MDI, licensed for the prophylactic management of mild, moderate or severe asthma in adults or children. It is a lower cost option than the current beclometasone dipropionate inhaler - Clenil Modulite®.</p> <p>Further relevant information: Soprabec is therapeutically equivalent to Clenil Modulite and its design and functioning are equivalent to those of Clenil Modulite®. Patients currently receiving treatment with Clenil Modulite® can be reviewed and switched to equivalent doses of Soprobec®.</p> <p>Please note - The recommended total daily dose of Soprobec® or Clenil Modulite® is higher than that for Kelhale® and Qvar® and therefore patients cannot be swapped between these without adjustments to their dose.</p>	<p>Approved for inclusion on the formulary as first line for “beclomethasone only” MDI, with a GREEN status.</p>

Product	Summary	Decision
Kelhale inhaler®	<p>Introduction: Kelhale® is a new brand of beclomethasone MDI containing extra fine particles. It offers a low cost option for beclomethasone dipropionate (extrafine aerosol) inhaler than Qvar®, for use in adults. Kelhale® is not recommended for individuals under 18 years old while Qvar® is not recommended for individuals under 12 years old.</p> <p>Further relevant information: Kelhale® is therapeutically equivalent to Qvar® and therefore adult patients currently receiving treatment with Qvar® can be reviewed and switched to equivalent doses of Kelhale®.</p> <p>Please note - The recommended total daily dose of Kelhale® (and Qvar®) beclomethasone dipropionate (extra fine particles) is lower than that for Clenil Modulite® and Soprobeq® and therefore patients cannot be swapped between these without adjustments to their dose.</p>	<p>Approved for inclusion on the formulary as first line for beclomethasone dipropionate (extrafine aerosol) MDI, for adults only (individuals 18 years and over), with a GREEN status.</p>

UPDATES

Antimicrobial Guidelines

A Lincolnshire primary care antimicrobial guideline, based on National NICE/PHE will be available on the PACEF website shortly. The Lincolnshire version of this guidance has been adapted to take into account local resistance patterns and Lincolnshire antimicrobial guidelines.

A PACEF briefing paper detailing the changes from the national guidance is also included on the website for reference.

Pain Management Guidance and quick reference guide

The one-page summary 'Lincolnshire Primary Care — Managing Non-malignant Chronic/Persistent Pain One-Page Guide' has been developed to support primary care prescribers and patients in making the best choices in relation to medicines prescribed to help ease pain. This summary does not include management of pain in end of life settings or of disease specific treatments which result in pain reduction (e.g. interventions for angina).

The more detailed 'Lincolnshire Primary Care Pain Management Guidance 2019' document aims to provide guidance to support the one page summary and support conversations and treatment decisions with patients regarding pain management. Copies of these will be sent to all medical practices and will be available on the PACEF website.

Produced by:
Medicines Management & Optimisation Service
Optum Health Systems Support

November 2019



T 020 7121 0560 | E info@optum.co.uk | optum.co.uk

10th Floor, 5 Merchant Square, Paddington, London, W2 1AS

Optum® is a registered trademark of Optum, Inc. in the U.S. and other jurisdictions. All other brand or product names are trademarks or registered marks and the property of their respective owners. Because we are continuously improving our products and services, Optum reserves the right to change specifications without prior notice. Optum is an equal opportunity employer.

© 2017 Optum, Inc. All rights reserved.